Salt Lake City, January 10, 2022 /GlobeNewswire/ — CenExel Clinical Research, Inc., (“CenExel”) announces the acquisition of California Neuroscience Research (“CenExel CNR”), a clinical research facility in Los Angeles with two decades of experience in neurological...
News at CenExel
Esketamine Receives Support from 2 FDA Committees
Esketamine, a drug developed by Johnson & Johnson for the treatment of depression has received support from two FDA committees. Final FDA approval is expected by March 2019. The drug has been approved for use in treatment resistant depression. From the...
Depression Treatment Gaithersburg
Depression treatment Gaithersburg. If you are experiencing depression and no medications have really helped, maybe one of our trials will.
Depression Research Study Participants Needed
Depression research study participants needed to take part in several clinical research trials exploring the effects of rapastinel, esketamine, and ketamine like compounds. Generally, research participants for these trials should: Be diagnosed with major depression Be...
Treatment Resistant Depression Clinical Trials Maryland
Treatment resistant depression clinical trials Maryland. We work with patients nationwide and in the Baltimore-Washington area.
Esketamine Clinical Trials 2019 Gaithersburg Washington DC Baltimore
Esketamine clinical trials 2019- we are currently offering paid clinical trials for esketamine and ketamine like compounds. Contact us to learn more.